These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23444692)

  • 1. Ethical considerations for NIH funded highly transmissible H5N1.
    Salhanick M
    Pharos Alpha Omega Alpha Honor Med Soc; 2013; 76(1):6-9. PubMed ID: 23444692
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospecting the influenza hemagglutinin to develop universal vaccines.
    Donis RO; Cox NJ
    Clin Infect Dis; 2011 Apr; 52(8):1010-2. PubMed ID: 21460315
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of the safety and immunogenicity of H5N1 pandemic influenza vaccines.
    Leroux-Roels I
    Bull Mem Acad R Med Belg; 2011; 166(1-2):18-24. PubMed ID: 22375487
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inactivated subvirion influenza A (H5N1) vaccine.
    Johansson BE; Brett IC
    N Engl J Med; 2006 Jun; 354(25):2724-5; author reply 2724-5. PubMed ID: 16790710
    [No Abstract]   [Full Text] [Related]  

  • 6. Influenza: options to improve pandemic preparation.
    Rappuoli R; Dormitzer PR
    Science; 2012 Jun; 336(6088):1531-3. PubMed ID: 22723412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology. Flu antibodies stir new hope for treatment, vaccine.
    Leslie M
    Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602
    [No Abstract]   [Full Text] [Related]  

  • 8. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.
    Lipatov AS; Hoffmann E; Salomon R; Yen HL; Webster RG
    J Infect Dis; 2006 Oct; 194(8):1040-3. PubMed ID: 16991078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIOSECURITY. Flu study raises questions about U.S. ban.
    Cohen J
    Science; 2015 Sep; 349(6253):1153. PubMed ID: 26359382
    [No Abstract]   [Full Text] [Related]  

  • 10. Influenza virus hemagglutinin as a vaccine antigen produced in bacteria.
    Sączyńska V
    Acta Biochim Pol; 2014; 61(3):561-72. PubMed ID: 25195143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).
    Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ
    Vaccine; 2009 Dec; 27(52):7451-8. PubMed ID: 19450640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic?
    Pappaioanou M
    Comp Immunol Microbiol Infect Dis; 2009 Jul; 32(4):287-300. PubMed ID: 19318178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pandemic vaccines].
    Floret D
    Arch Pediatr; 2010 Jun; 17(6):906-7. PubMed ID: 20654954
    [No Abstract]   [Full Text] [Related]  

  • 15. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistency.
    Wagner R; Pfleiderer M
    Expert Rev Vaccines; 2012 Aug; 11(8):881-3. PubMed ID: 23002967
    [No Abstract]   [Full Text] [Related]  

  • 17. Influenza vaccines: the good, the bad, and the eggs.
    Schultz-Cherry S; Jones JC
    Adv Virus Res; 2010; 77():63-84. PubMed ID: 20951870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.